AVEO Oncology announces topline results from TIVO-3 trial of tivozanib (FOTIVDA®)
AVEO Oncology data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma. The trial met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival. February 16, 2019